

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number
WO 2006/065821 A2

(51) International Patent Classification:

A61K 39/39 (2006.01) C12N 15/90 (2006.01)
C07K 14/535 (2006.01)

(21) International Application Number:

PCT/US2005/045080

(22) International Filing Date:

12 December 2005 (12.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/636,361 14 December 2004 (14.12.2004) US

(71) Applicant (for all designated States except US): **THERAPEUTIC HUMAN POLYCLONALS, INC.** [US/US];
2105 Landing Drive, Mountain View, California 94043 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUELOW, Roland** [DE/US]; 2747 Ross Road, Palo Alto, California 94303 (US). **PLATZER, Josef** [DE/DE]; Schlierseeweg 9, 82538 Gerestried (DE).

(74) Agent: **DREGER, Ginger, R.**; Heller Ehrman LLP, 275 Middlefield Road, Menlo Park, California 94025 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: IMPROVED DNA IMMUNIZATION WITH RECOMBINASE/TRANSPOSASE



(57) Abstract: The present invention relates to improved methods to immunize/vaccinate or stimulate the immune system of animals, including humans, using vectors containing expression cassettes that encode for the DNA of one or more protein/peptide antigens and/or adjuvants, in particular, cytokines like GMCSF, F1t3L, interleukins, and the like, which can be encoded by DNA as well, also recombinase mediated integration. Adjuvants known to increase immune responses following DNA vaccination. In addition, the vectors contain one or more sites recognized by a recombinase/transposase, which catalyzes the insertion of the vector into the genome of transfected cells. Stable integration of the plasmid vector into the genome of transfected cells results in higher and longer-lasting expression of the encoded protein(s), and increases the immune response in the vaccinated animal. The present invention also relates to adjuvant compositions comprising the novel polypeptide, rabbit GMCSF, for boosting antibody production in rabbits.



WO 2006/065821 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

IMPROVED DNA IMMUNIZATION WITH RECOMBINASE/TRANSPOSASE

Field of the Invention

This invention relates to the field of DNA vaccines and adjuvants. Specifically, the present invention relates to improved methods to immunize/vaccinate or stimulate the immune system of animals, including humans, using vectors containing expression cassettes that encode one or more protein/peptide antigens and/or adjuvants and a recombinase that mediates the integration of the DNA into the genome of the animal. The present invention also relates to adjuvant compositions comprising a novel polypeptide, rabbit GMCSF, for boosting antibody production in rabbits.

Background Art

The use of vaccines for the immunization of animals requires the reproducible production of protein antigens, which may be difficult and expensive. Whole, or usually, parts of the whole organism, toxin, or antigen is/are used for immunization. Vaccines require high or mostly, repeated doses of the antigen to be administered for maintaining a certain level of immunity in the host. Further, vaccine development is severely limited by the availability of useful antigens that can elicit a feasible response in an animal. The use of adjuvants for the enhancement of the immune response in an animal is well known in the art. A wide variety of adjuvants have been used, for example, mineral oil or oil containing adjuvants like complete Freund's adjuvant (FCA), incomplete Freund's adjuvant, Ribi adjuvant, Titermax, etc., adjuvants derived from bacteria like MDP (muramyl dipeptide), lipid A, lipopolysaccharide (LPS), etc., mineral compounds like aluminium phosphate, aluminium hydroxide and calcium phosphate, etc., liposomes, saponins complexed to membrane protein antigens (immune stimulating complexes), etc. Many adjuvants are toxic or cause mild to severe side effects, while some may only elicit a weak immune response in the host. Therefore, the development of safe and effective adjuvants is a continuing challenge. One newer approach in adjuvant development is the use of biological immunostimulatory adjuvants, like cytokines, as adjuvants.

Genetic or DNA immunization is known in the art and uses genes or the DNA encoding the antigenic protein of interest, rather than the polypeptides themselves, as the source of the immunogen. This is based on raw materials that is easy and inexpensive to manufacture, and can also be produced reproducibly. The host's cells take up the DNA that is introduced, and express the encoded antigen by normal cellular mechanisms. The antigen is then presented on the cell

surface with host MHC class I and class II molecules where contact with immunocompetent cells evokes an immune response. Thus, without increasing the amount of antigen in the initial vaccine, or without repeated administration of the vaccine, immunity lasts for an extended period of time. Immunization of mice with naked DNA encoding a herpes simplex virus (HSV) protein was reported by Manickan et al., *J Clin Invest* 100: 2371-2375 (1997). Boyle et al., *Proc Natl Acad Sci USA* 94: 14626-14631 (1997) reported that DNA immunization induces rapid CTL responses, and produces higher avidity antibodies than traditional protein immunization. DNA vaccines for HIV/AIDS have been produced and tested in various animal models, including non-human primates, and in human clinical trials. See, e.g. Robinson et al., *Ann N Y Acad Sci* 772: 209-211 (1995); Yasutomi et al., *J Virol* 70:678-681 (1996); MacGregor et al., *J Infect Dis* 178: 92-100 (1998). In addition to infectious diseases, DNA immunization is believed to have the potential as a means for cancer immunotherapy (see, e.g., Srinivasan and Wolchok, *J Transl Med* 2: 12 (2004)). DNA vaccines have also been recommended for allergy treatment (see, e.g., Hartl et al., *Methods* 32: 328-39 (2004)).

Several factors influence the outcome of DNA vaccination, including, the method and location of immunization, the form of the immunogen, the immunization regimen, the presence or absence of adjuvants or the co-administration of biological adjuvants like cytokines, co-administration of other costimulatory molecules, the presence or absence of immunostimulatory sequences (ISS) within the DNA, etc. For example, it was observed that the DNA from bacteria, but not vertebrates, could induce a nonspecific immune response, which appeared to be due to differences in the frequency of unmethylated cytosine-phosphate-guanine dinucleotides (CpG) found in the two genomes. Further, it was found that DNA vaccination with a plasmid DNA containing the CpG and ISS sequences induced a more vigorous antibody and CTL response than an otherwise identical vaccine without the ISS sequence. Other important factors also influencing the immune response to DNA vaccination is the form of the encoded antigen, in particular, whether the antigen is expressed as a cytoplasmic or secreted protein, and the level of expression of the encoded antigen and/or adjuvants. In general, the higher and longer-lasting the expression, the more vigorous the immune response.

Successful DNA vaccination has been demonstrated via a number of different routes, including intravenous, intramuscular, intrasplenic and intrahepatic routes. For the generation of an antibody response, multiple studies have reported that gene gun immunization is far more efficient than needle injection, eliciting similar levels of antibody responses with 100- to 5000-fold less DNA. The optimal regimen for administering a DNA vaccine (e.g. dose, number, and/or

frequency of immunizations) is far from determined and requires optimization for each individual antigen. Most studies indicate that multiple injections are necessary to maximize the immune response.

Of the different ways to modulate the immune response via DNA immunization, the most promising way may be through the coadministration of biological adjuvants such as cytokines. The GM-CSF gene is one of the most studied genetic adjuvants, and was shown to be an effective immune stimulator following DNA vaccination. Additional booster effects were observed when the GM-CSF gene was combined with other adjuvants like the FMS-like tyrosine kinase 3 ligand (Flt3L) gene or the IL-4 gene. Recently, the combination of GM-CSF and Flt3L was shown to result in high antibody titers in mice, in most (84%) of the more than 130 tested antigens; Chambers *et al.*, *Nat. Biotechnol.* 21(9): 1088-92 (2003).

Even so, DNA immunization requires more effective methods that result in higher and longer-lasting expression of the encoded antigen proteins and/or adjuvants.

Summary of the Invention

The present invention concerns a method for DNA immunization or vaccination or stimulation of the immune system of animals using recombinase/transposase mediated integration of expression cassettes encoding one or several antigens and/or adjuvants into the genome of transfected cells in vaccinated animals and also provides adjuvant compositions for boosting antibody production of DNA immunized animals.

In one aspect, the invention provides a novel adjuvant sequence of rabbit GMCSF polypeptide of SEQ ID NO: 1. Further, the invention provides a chimeric molecule comprising the rabbit GMCSF polypeptide of SEQ ID NO: 1 fused to a heterologous amino acid sequence. In one embodiment, the heterologous amino acid sequence is an epitope sequence. In another embodiment, the heterologous amino acid sequence is an immunoglobulin sequence. In a further aspect of this embodiment, the immunoglobulin sequence is an Fc region of an immunoglobulin.

The present invention also provides nucleotide sequences encoding the rabbit GMCSF polypeptide of SEQ ID NO: 1. Further, the invention provides a vector or an expression cassette comprising the nucleotide sequence(s) encoding the rabbit GMCSF polypeptide of SEQ ID NO: 1.

The present invention also provides an isolated host cell transformed with the nucleic acid sequences encoding the rabbit GMCSF polypeptide of SEQ ID NO: 1.

In another aspect, the invention concerns a method for immunizing or vaccinating an animal, comprising: (i) administering at least one DNA construct comprising at least one expression cassette that encodes for an antigen, and a first recombination site; (ii) stimulating the immune system of said animal by administering at least one adjuvant to said animal; and, (iii) administering a recombinase that mediates the integration of said expression cassette into the genome of said animal comprising a second recombination site, wherein, said antigen is expressed.

In all aspects of the invention, the adjuvant may be a traditionally used adjuvant or may be introduced as a polypeptide or as a nucleic acid encoding the adjuvant. When the adjuvant is introduced as a DNA, the method involves (i) the administration of the adjuvant into the animal as a DNA construct comprising an expression cassette that encodes for the adjuvant, and, a first recombination site; and, (ii) a recombinase that mediates the integration of the expression cassette into the genome of the animal comprising a second recombination site, wherein, the adjuvant is expressed.

In all aspects, preferred antigen(s) include, but are not limited to, viral, bacterial, fungal, protozoal antigens and antigens associated with diseases like infection, inflammation, cancer, asthma/allergy, autoimmune diseases, multiple sclerosis, sepsis/toxic shock, rheumatoid arthritis, allograft rejections, psoriasis, etc. In a preferred embodiment, the antigen is CD20.

In all aspects, preferred adjuvant(s) include, but are not limited to, GMCSF, Flt3L, interleukins like IL-1 α and β , IL-2, IL-12, IL-15, IL-18, IL-4, IL-5, IL-6, IL-10, TNF- α , TNF- β , IFN- γ , etc. and co-stimulatory molecules like TCA3, CD80 (B7.1), CD86 (B7.2), CD40 ligand (CD154), MCP-1, MIP-1 α , β , RANTES, etc. In a preferred embodiment, the adjuvant is the rabbit GMCSF of SEQ ID NO: 1.

In one embodiment, the antigen-encoding expression cassette and the adjuvant-encoding expression cassette are part of one DNA construct. In another embodiment, the antigen-encoding expression cassette and the adjuvant-encoding expression cassette are on separate DNA constructs.

In all aspects of the invention, the recombinase may be administered as a polypeptide, or as an RNA molecule encoding the recombinase, or as a DNA construct comprising an expression cassette encoding the recombinase.

In one embodiment, the recombinase may be a site-specific recombinase expressed by a phage. In a further aspect of this embodiment, the phage recombinase may be selected from the group consisting of ϕ C31, phage R4 and TP901-1.

5 In another embodiment, the recombinase may be a site specific recombinase selected from the group consisting of a Cre-recombinase, a Cre-like recombinase, a Flp recombinase and an R recombinase.

In yet another embodiment, the recombinase may be a transposase or a retrotransposase. In a further aspect, the transposase is selected from the group consisting of AC7, Tn5, Tn916, Tn951, Tn1721, Tn2410, Tn1681, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101,
10 Tn903, Tn501, Tn1000, Tn1681, tn2901, AC transposons, Mp transposons, Spm transposons, En transposons, Dotted transposons, Mu transposons, Ds transposons, En transposons, and I transposons. In a yet another aspect, the transposase is a eukaryotic transposase.

In one embodiment, the first and second recombination sites share at least 90% sequence identity. In another embodiment, the first and second recombination sites share less than 90%
15 sequence identity. In a further embodiment, the first recombination site comprises a bacterial genomic recombination site and the second recombination site comprises a phage recombination site. In yet another embodiment, the bacterial genomic recombination site is attB and the phage recombination site is attP. In yet another embodiment, the first recombination site comprises an attB site, and said second recombination site comprises a pseudo-attP site. In yet another
20 embodiment, the first recombination site comprises a pseudo-attB site, and said second recombination site comprises an attP site.

In a certain embodiment, the recombinase-mediated recombination results in a site that is no longer a substrate for the recombinase.

In one embodiment of the invention, the DNA construct(s) may be circular. In another
25 embodiment, the DNA construct(s) may be linear.

In a certain aspect, the invention provides a method for producing antibodies in an animal, comprising: (i) administering at least one DNA expression cassette encoding an antigen, a recombination site, and a recombinase that mediates the integration of the DNA expression cassette into the genome of the animal; (ii) optionally administering at least one adjuvant; (iii)
30 harvesting a serum sample after several days from the animal; (iv) identifying and optionally, purifying antibodies to the administered antigen(s) from the serum sample.

As indicated before, the adjuvant may be a traditionally used adjuvant or may be introduced as a polypeptide or as a nucleic acid encoding the adjuvant.

In all aspects, preferred animals include humans and non-human animals like rabbits, birds (e.g. chicken, turkey, ducks, geese, etc.), rodents, cows, pigs, sheep, goats and horses. In a preferred embodiment, the non-human animal is a rabbit.

A preferred group of non-human animals includes non-human transgenic animals carrying an exogenous immunoglobulin translocus. In one embodiment, the non-human transgenic animal is a gene converting animal. In a preferred embodiment, the exogenous immunoglobulin translocus is a human or humanized immunoglobulin heavy and/or light chain sequence.

Brief Description of the Drawings

Figure 1 shows the amino acid sequence of rabbit GMCSF (SEQ ID NO:1).

Figure 2 shows a nucleic acid sequence (SEQ ID NO:2) encoding the rabbit GMCSF polypeptide. The coding sequence is highlighted.

Figure 3 shows an amino acid alignment of rabbit GMCSF (SEQ ID NO:1) with other GMCSF molecules (SEQ ID NOs: 7-19) derived from various animals.

Figure 4 shows an expression plasmid with three expression cassettes encoding rabbit GM-CSF, rabbit FLT3-L and human CD20. The plasmid also contains a recombinase recognition sequence (RRS) for recombinase-mediated integration of the expression cassettes into the genome of transfected cells.

Detailed Description of the Invention

A. Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.*, *Dictionary of Microbiology and Molecular Biology* 2nd ed., J. Wiley & Sons (New York, NY 1994); Lowrie and Whalen, *DNA Vaccines: Methods and Protocols*, Humana Press (1999); Constantin A. Bona and Adrian Bot, *Genetic Immunization*, Kluwer Academic/Plenum Publishers (New York, NY 2000); Koprowski and Weiner, *DNA Vaccination/Genetic Vaccination*, Springer (Berlin, New York, 1998); "Molecular Cloning: A Laboratory Manual", 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); and "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987) provide one skilled in the art with a general guide to many of the terms, methods and protocols used in the present application.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

The term "immunization" is used in the broadest sense and refers to the introduction of antigens into the body in order to stimulate the development of immunity. "DNA immunization" or "genetic immunization" uses DNA encoding one or more antigens and/or adjuvants, instead of the proteins/polypeptides themselves, to produce and/or boost immunity.

The term "vaccination" usually refers to the introduction of a killed or attenuated pathogen into the body in order to promote protective immunity.

In "DNA vaccination" (also known as "genetic vaccination"), instead of the killed or attenuated pathogen, one or more genes of one pathogen or different pathogens is/are introduced into the body. As a result, it is possible to vaccinate against variants of the same pathogen, or against several different pathogens, at the same time.

The term "DNA construct" as used herein refers to a polynucleotide molecule, which contains one or several structural gene(s) of interest, recombination sequences and other DNA sequences necessary for maintenance, replication, selection of the DNA construct. A DNA construct may contain one or more of the "expression cassettes" described below. A DNA construct can be any vector, like a plasmid, any viral vector including, but not limited to,

retroviral, adenoviral, lentiviral, a cosmid, etc. The term "retroviral vector" also refers to a DNA construct and refers to a retrovirus or retroviral particle, which is capable of entering a cell and integrating the retroviral genome into the genome of the host cell. The DNA construct can be either linear, or preferably, circular.

5 The term "expression cassette" refers to a polynucleotide molecule, which contains one or several structural gene(s) of interest operatively linked to their respective regulatory sequences that promote expression of the encoded gene of interest, and optionally, further DNA sequences that encode for domains required for various functions such as, for timely expression, to facilitate proper protein folding, for uptake by antigen presenting cells, for B-cell activation, T- helper cell
10 recognition etc. In the context of this invention, expression cassettes include one or more antigen expression cassettes, adjuvant expression cassettes, recombinase expression cassettes and the like.

 The term "recombinase" as used herein refers to a group of enzymes that can facilitate recombination, preferably, site specific recombination, between defined sites, called
15 "recombination sites," where the two recombination sites are physically separated within a single nucleic acid molecule or on separate nucleic acid molecules. The sequences of the two defined recombination sites are not necessarily identical. Within the group of recombinases there are several subfamilies including "integrases" (for example, like Cre, Cre-like, FLP and λ integrase), "resolvases/invertases" (for example, ϕ C31 integrase, R4 integrase, and TP-901 integrase). The
20 term "recombinase" also includes, but is not limited to, prokaryotic or eukaryotic transposases, viral or *Drosophila* copia-like or non-viral reterotransposons that include mammalian reterotransposons. Exemplary prokaryotic transposases include transposases encoded in the transposable elements of Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101, Tn501, Tn903, Tn1000, Tn1681, Tn2901, etc. Eukaryotic transposases include transposases encoded in
25 the transposable elements of *Drosophila mariner*, *sleeping beauty* transposase, *Drosophila P* element, maize Ac and Ds elements, etc. Retrotransposases include those encoded in the elements of *L1*, *Tol2 Tc1*, *Tc3*, *Mariner (Himar 1)*, *Mariner (mos 1)*, *Minos*, etc. Transposases may also be selected from Mp, Spm, En, dotted, Mu, and I transposing elements.

 The term "wild-type recombination site" as used herein refers to a recombination site
30 normally used by a recombinase, such as an integrase.

 By "pseudo-recombination site" is meant a site at which recombinase can facilitate recombination even though the site may not have a sequence identical to the sequence of its wild-type recombination site.

In the context of the present invention, the terms "first recombination site" or "second recombination site" can be any wild-type or pseudo-recombination site, such as, for example, an attB, attP, pseudo-attB, or a pseudo-attP site.

The term "recombinase-mediated integration of the expression cassette" is used to refer to integration mediated by an encoded and expressed recombinase, that facilitates specific integration of the expression cassette into the genome of a cell rather than random integration.

"Adjuvant" is any compound or composition whose purpose is to enhance the immune response to a particular antigen of interest. Any adjuvant, irrespective of the mechanism by which it enhances the immune response, is useful in this invention.

"Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.

The term "non-human animal" as used herein includes, but is not limited to, mammals such as, for example, non-human primates, rodents (e.g. mice and rats), and non-rodent animals, such as, for example, rabbits, pigs, sheep, goats, cows, pigs, horses and donkeys. It also includes birds (e.g., chickens, turkeys, ducks, geese and the like). The term "non-primate animal" as used herein refers to mammals other than primates, including but not limited to the mammals specifically listed above.

The terms "polynucleotide" and "nucleic acid" are used interchangeably, and, when used in singular or plural, generally refer to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. The DNA origin may be from genomic DNA, cDNA or through gene synthesis. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "polynucleotide"

specifically includes cDNAs. The term includes DNAs (including cDNAs) and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "polynucleotides" as defined herein. In general, the term "polynucleotide" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.

B. Detailed Description

The present invention concerns an improved method for the DNA immunization or vaccination of animals such as mammals, including humans. The method uses DNA expression cassettes encoding an antigen (such as a protein from a pathogen or parts thereof, a tumor antigen, etc.), rather than the antigen itself, in order to produce long-lasting immunity. The improved method can also be used to enhance or stimulate immunity in an animal using genetic adjuvants, that is, adjuvants encoded for by a DNA expression cassette, for longer lasting enhancement of immunity. In this method, the DNA encoding the antigen or the adjuvant is introduced and subsequently, integrated into the genome of the animal via a recombinase, preferably a site-specific recombinase, that facilitates this integration into the genome. This invention further provides novel nucleic acid and polypeptide sequences for the rabbit GMCSF adjuvant. Thus, for example, antibodies, including humanized antibodies, can be generated in animals like rabbits, using this adjuvant.

More specifically, site-specific integration of the antigen and/or adjuvant expression cassettes comprises administration of (i) one or several circular DNA constructs comprising one or several antigen and/or adjuvant encoding expression cassettes and a first recombination site recognized by a site-specific recombinase, and (ii) a site specific recombinase. Administration of the DNA constructs into the animal using any of the methods discussed below, results in the transfection of cells. The genome of transfected cells comprise a second recombination site native to the genome, and thus, site-specific recombination between the first and the second recombination sites facilitated by the recombinase results in stable and a higher incidence of integration of the DNA expression cassette(s) into the cellular genome of the animal. Thus, recombinase-mediated DNA immunization method results in higher and longer-lasting expression of the encoded antigenic and/or adjuvant protein(s).

In one aspect of the invention, the methods comprise DNA that encodes for antigens. The origin of the antigenic DNA includes, but is not limited to, genomic DNA, cDNA or sequences obtained by gene synthesis. Antigens may be identified by genome-wide searches for novel useful sequences using strategies known in the art or by bioinformatic screens.

5 By antigenic DNA is meant DNA sequences from an infectious pathogen including, but are not limited to, bacteria, virus, protozoa, *Clamylidia*, *Leishmania*, *Toxoplasma*, *Plasmodium*, fungus including yeast, etc. or parts of the antigen thereof.

Exemplary bacterial antigens, which are encoded for by their DNA in the present invention include, antigens from *Staphylococcus aureus*., recombinant versions of virulence
10 factors such as alpha-toxin, adhesin binding proteins, collagen binding proteins, and fibronectin binding proteins. Exemplary bacterial antigens also include other proteins of *S. aureus*, *Pseudomonas aeruginosa*, enterococcus, enterobacter, and *Klebsiella pneumoniae*, *Bordetella* (cya C and cya A genes), etc. Further exemplary bacterial antigens include, but are not limited to, the coding sequences of capsular antigens, recombinant versions of outer membrane proteins,
15 fibronectin binding proteins, antigens and toxins from *Pseudomonas aeruginosa*, enterococcus, enterobacter, *Klebsiella pneumoniae*, etc.

Exemplary antigens for the generation of antibodies against fungi include outer membrane proteins of fungi, such as, for example, *Candida albicans*, *Candida parapsilosis*, *Candida tropicalis*, and *Cryptococcus neoformans*, etc.

20 Exemplary antigens, the coding sequences of which can be used to generate antibodies against viruses include, but are not limited to, the envelop proteins and attenuated versions of viruses which include, but are not limited to, influenza, HIV-1/2 (especially, gag, pol, rev, nef and envelope proteins like gp120, env, etc.), rabies, respiratory syncitial virus (RSV) (particularly the F-Protein), Hepatitis C virus (HCV), Hepatitis B virus (HBV), cytomegalovirus
25 (CMV), EBV, rotavirus, Ebola and HSV-1 and 2 (Herpes simplex virus), etc.

In another aspect of the invention, by antigen is also meant antigens that elicit antibody responses, wherein the antibody is useful for the therapeutic treatment of diseases like cancer. Exemplary cancer related antigens useful in the preparation of therapeutic antibodies include, but are not limited to, carcinoembryonic antigen (CEA) and 17-1A for colon cancer; T cell receptor
30 V β for cutaneous T cell lymphoma; Her-2-neu antigen for breast cancer; CD19, CD20, CD22 and CD53 antigens for B cell lymphomas; prostate specific membrane antigen (PMSA) for prostate cancer; VEGF (general); CA125 for ovarian cancer; EpCAM for colorectal cancer, etc.

By antigen is further meant antigens eliciting antibody responses, wherein the antibody is useful for the therapeutic treatment of diseases other than cancer, including, but not limited to, asthma/allergies with exemplary antigens like CD23, IgE, IL-5, IL-4, etc.; autoimmune diseases with exemplary antigens like glycosyl CD3 (for Type I diabetes), CD3, CD4, CD40L (for SLE or lupus), etc.; multiple sclerosis with exemplary antigens like VLA-4, CD40L, CD11/18, etc.; inflammation and/or sepsis/ toxic shock with exemplary antigens like TNF α and β , CD14, etc.; rheumatoid arthritis with exemplary antigens like complement C5, TNF α and β , CD4, etc.; allograft rejections with exemplary antigens like CD147, CD18, CD40L, β 2 integrin, CD3, CD4, CD25, etc.; psoriasis with exemplary antigens like IL-8, CD11a, E-selectin, ICAM-3, CD80, CD2, CD3; wherein, such resulting immune responses may be used in the preparation of immunovaccines to combat the disease.

By antigen is also meant antigens that elicit an antibody response, wherein the antibody is an agonistic or a mimetic antibody useful for treating a disease, for example, like thrombocytopenia. Here, the mimetic antibody, anti-c-MPL, is designed to mimic the activity of TPO (thrombopoietin) that is responsible for platelet production and hence, is useful as a therapeutic antibody.

In yet another aspect of the invention, the method for DNA immunization uses an adjuvant. Adjuvants of the present invention include, but are not limited to, traditionally used adjuvants like mineral oil or oil containing adjuvants like complete Freund's adjuvant (FCA), incomplete Freund's adjuvant, Ribi adjuvant, Titermax, etc., adjuvants derived from bacteria like MDP (muramyl dipeptide), lipid A, lipopolysaccharide (LPS), etc., mineral compounds like aluminium phosphate, aluminium hydroxide and calcium phosphate, etc., liposomes, saponins complexed to membrane protein antigens (immune stimulating complexes), cytokines, co-stimulatory molecules, bacterial DNA, CpG, etc.

In one embodiment, the adjuvant of the present invention is any cytokine like GM-CSF, IL-1 α and β , IL-2, IL-12, IL-15, IL-18, IL-4, IL-5, IL-6, IL-10, TNF- α , TNF- β , IFN- γ , or the like. In another embodiment, the adjuvant is a co-stimulatory molecule like TCA3, CD80 (B7.1), CD86 (B7.2), CD40 ligand (CD154), MCP-1, MIP-1 α , β , RANTES, or the like.

In another embodiment of the present invention, the cytokine or co-stimulatory adjuvant maybe introduced as a polypeptide, as an mRNA or as a DNA encoding the adjuvant or co-stimulatory molecule. Further, a combination of adjuvants or co-delivery of more than one adjuvant may be also be used. Ideally, the synergy between the combination of adjuvants being

used is evaluated and their combined ability to elicit both, humoral and cell-mediated immune responses, even if administered by various routes.

In an important aspect of the invention, the methods utilize a recombinase to facilitate integration of the antigenic and/or adjuvant expression cassette(s), or even the recombinase expression cassette, into the genome of the animal. Genomic integration of expression cassettes may be facilitated by site-specific or random recombination. In a preferred embodiment, the method requires a site-specific recombinase that facilitates genomic integration of any of the expression cassettes at a specific site into the genome of the animal.

Site specific recombinases are enzymatically active proteins that catalyze a reciprocal double-stranded DNA exchange between two DNA segments. Such recombinases recognize specific sequences in both partners of the exchange and may function as sole proteins, or may require the presence of accessory factors for function. While the mechanism of catalysis might be different for different types of site-specific recombinases, they are all included herein, regardless of the underlying mechanism, and are suitable for the practice of the present invention.

Site-specific recombinases are typically, but not exclusively, prokaryotic. The two largest families of site-specific recombinases are λ integrase-like enzymes and the resolvase/invertases. Members of the two families significantly differ in their amino acid sequences, and in their mechanisms of catalysis. Recombination by members of the λ integrase family involves the formation and resolution of a Holliday junction intermediate during which the DNA is transiently attached to the enzyme through a phosphotyrosine linkage. The resolvase/invertase family of enzymes act via a concerted, four-strand staggered break and rejoining mechanism during which a phosphoserine linkage is formed between the enzyme and the DNA.

Thus, for example, the genome of the broad host range *Streptomyces* temperate phage, Φ C31 is known to integrate into the host chromosome with the aid of an enzyme that is a member of the resolvase/invertase family of site-specific recombinases. For further details see, e.g. Thorpe and Smith, *Proc. Natl. Acad. Sci. USA*, 95(10):5505-5510 (1998). The phage C31 integrase has been shown to mediate efficient integration in the human cell environment at *attB* and *attP* phage attachment sites on extrachromosomal vectors. ϕ C31 and R4 belong in the integrase family of site-specific recombinases, while TP901-1 belongs to the family of extended resolvases. The R4 integrase is a site-specific, unidirectional recombinase derived from the genome of phage R4 of *Streptomyces parvulus*. The site-specific integrase TP901-1 is encoded

by phage TP901-1 of *Lactococcus lactis subsp. cremoris*. λ is a temperate bacteriophage that infects *E. coli*. The phage has one attachment site for recombination (attP) and the *E. coli* bacterial genome has an attachment site for recombination (attB). In the context of the present invention, wild-type recombination sites can be derived, for example, from the homologous system and associated with heterologous sequences. Thus, the attB site can be placed in other systems to act as a substrate for an integrase. In one embodiment, the recombinase may catalyze recombination between a bacterial genomic recombination site (attB) and a phage genomic recombination site (attP), or the first site may comprise a pseudo-attB site and/or the second site may comprise a pseudo-attP site, or vice versa. In another embodiment, the recombinase mediates production of recombination sites that are no longer substrates for the recombinase (Groth et al., *Proc. Nat. Acad. Sci.*, 2000, 97: 5995-6000; Olivares et al., *Nature Biotechnol.* 2002, 20(11):1124-8); (Thyagarajan et al., *Mol. and Cell. Biol.*, 2001, 21: 3926-3934); Hollis et al., *Repro. Biol. and Endocrinol.*, 2003, 1:79. Thus, in the present invention, the recombinase may be a site-specific recombinase encoded by a phage selected from the group consisting of λ integrase, ϕ C31, TP901-1, and R4. Other known and frequently used site-specific recombinases include Cre and FLP or the like (see, e.g. Bouhassira et al., *Blood* 88 (Suppl. 1), 190a (1996); Bouhassira et al., *Blood* 90:3332-3344 (1997); Seibler & Bode, *Biochemistry* 36:1740-1747 (1997); Seibler et al., *Biochemistry* 37:6229-6234 (1998); Bethke & Sauer, *Nucl. Acids Res.* 25:2828-2834 (1997)). The target of the Cre recombinase is a 34-bp sequence *loxP* sites that consists of two inverted 13-bp Cre-binding sites separated by an eight base spacer within which the recombination occurs (Hoess & Abremski, *Proc. Natl. Acad. Sci. USA* 81:1026-1029 (1984)). Cre/*loxP* based cloning systems are commercially available, for example, from BD Biosciences-Clontech, Palo Alto, California (CreatorTM), or Invitrogen, Carlsbad, California (EchoTM). Flp targets the *frt* site. The use of Cre recombinase for site-specific recombination of DNA in eukaryotic cells is described in U.S. Patent No. 4,959,317. The use of site specific recombinase for the transfection of eukaryotic cells is described in U.S. Patent No. 6,632,672. Site specific recombination in general is described in U.S. Patent No. 4,673,640.

In yet another embodiment, the recombinase can be a transposase or a retrotransposase. Transposons or retrotransposases, are enzymes that catalyze their transposition by a cut and paste mechanism and thus, can be used for the transfer or insertion of any expression cassette. They provide non-viral and non-homologous methods for the insertion or transfer of any DNA sequence into the genomes of a wide range of species, including vertebrates like humans, bird, rodents, etc. For example, the *Drosophila* element *mariner* was shown to transpose itself into

chicken germ lines, Sherman et al., *Nature Biotechnol.*, 16:1050-1053 (1998). Long term transgene expression or efficient insertion of transposon DNA, using the *sleeping beauty* transposase system into mammalian systems like the mouse and human genomes have been demonstrated by Yant et al., *Nature Genetics*, 25: 35-41 (2000); Dupuy et al., *Proc. Nat. Acad. Sci.*, 99: 4495-4499 (2002) and Geurts et al., *Mol. Therapy*, 8: 108-117 (2003). Other transposases like *L1*, *Tol2 Tc1*, *Tc3*, *Mariner (Himar 1)*, *Mariner (mos 1)*, *Minos* have been shown to be active in vertebrate species and are thus useful for gene transfer or as insertional mutagenesis vectors, Largaespada, David A., *Repro. Biol. and Endocrinol.*, 1:80 (2003). Exemplary transposases include, but are not limited to, prokaryotic or eukaryotic transposases, viral, *Drosophila* copia-like or non-viral reterotransposons which include mammalian reterotransposons, etc. Prokaryotic transposases include transposases encoded in the transposable elements of Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101, Tn501, Tn903, Tn1000, Tn1681, Tn2901, etc. Eukaryotic transposases include transposases encoded in the transposable elements of *Drosophila mariner*, *sleeping beauty* transposase, *Drosophila P* element, maize Ac and Ds elements, etc. Retrotransposases include those encoded in the elements of *L1*, *Tol2 Tc1*, *Tc3*, *Mariner (Himar 1)*, *Mariner (mos 1)*, *Minos*, etc. Transposases may also be selected from Mp, Spm, En, dotted, Mu, and I transposing elements.

In a certain embodiment, the transposase may be a transposase selected from the group of AC7, Tn5, Tn916, Tn951, Tn1721, Tn2410, Tn1681, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101, Tn903, Tn501, Tn1000, Tn1681, Tn2901, AC transposons, Mp transposons, Spm transposons, En transposons, Dotted transposons, Mu transposons, Ds transposons, En transposons, I transposons and the like. Alternatively, an altered target site transposase or eukaryotic transposase, like *Drosophila P* element, *Drosophila mariner* element, or *sleeping beauty* transposase, and the like may be used.

In yet another embodiment, multiple copies of expression cassettes encoding antigen(s) and/or adjuvant(s) may be inserted into the genome of a eukaryotic cell by a "rolling replication" transposition. Tn1, Tn2, Tn3, Tn4, Tn5, Tn9, Tn21, Tn501, Tn551, Tn951, Tn1721, Tn2410 and Tn2603 are examples of rolling replication type transposons.

The recombinase may be introduced as an enzymatically active protein or in form of a recombinant expression plasmid encoding the recombinase. Alternatively, the expression of recombinase may be accomplished through introduction of messenger RNA encoding recombinase.

Thus, the invention concerns a method of DNA vaccination including transposase-mediated integration of expression cassettes encoding one or several antigens and/or adjuvants into the genome of transfected cells of vaccinated animals.

According to the present invention, the nucleic acids encoding the antigen, the
5 recombinase and the adjuvant may be added simultaneously or in any order. For example, the DNA encoding the antigen and the adjuvant may be added prior to the addition of the recombinase. Alternately, the recombinase may be introduced into the recipient cell before or concurrent with the introduction of the expression cassette comprising the coding sequence of
10 the desired antigen or antigens and/or the coding sequence of the desired adjuvant(s) as well as the recombinase-specific recognition sequence. Or, the nucleic acid(s) encoding the antigen, the recombinase and the recombinase-specific recognition sequence may be added first and the adjuvant, or the DNA encoding it may be added subsequently.

In one embodiment, the recombinase is introduced into the cell as a mRNA, e.g. by injection into male pronuclei with the aid of a micromanipulator. Alternatively, the recombinase
15 may be introduced into the recipient cell by a recombinant expression cassette (e.g. plasmid) encoding the recombinase. Such plasmids are known in the art and are either commercially available or can be readily made, and include the commercially available expression plasmid, pcDNA3, and its variants. Cre expression plasmids are also commercially available, and include, for example pBS 185 (CMV-CRE) (Clontech). In a further embodiment, the
20 recombinase is introduced into the recipient animal as an enzymatically active protein.

In the present invention, the DNA construct can be any vector like a plasmid, any viral vector, including, but not limited to, retroviral, adenoviral, lentiviral, cosmid, phage, etc. Further, the DNA construct can be either linear, or preferably, circular. The DNA constructs of the present invention can encode for the antigenic DNA, the adjuvant DNA and/or the recombinase
25 DNA on one construct, one two or more constructs, or on separate individual constructs. Each DNA construct may be simultaneously administered to the animal or, preferably, the adjuvant construct may be administered after the introduction and expression of the antigenic DNA expression cassette. The DNA constructs of the invention may further include DNA sequences necessary, for example, for its maintenance, replication, antibiotic selection, etc. Further, the
30 DNA constructs may encode for various functional DNA sequences, for example, immunostimulatory (ISS) sequences like CpG motifs, that trigger a more vigorous immune response, etc.

Routes of administration of the DNA constructs of the invention include injection, oral or intranasal delivery, etc, or by any other route known in the art or as described, for example, in U.S. Pat. No. 5,543,158, U.S. Pat. No. 5,641,515, and U.S. Pat. No. 5,399,363, all of which have been hereby incorporated by reference and is regardless of the mechanism by which they elicit an immune response. Injection can be subcutaneous, intradermal, intramuscula, intraperitoneal, intrasplenic, transdermal, etc. A preferred method for injecting the DNA constructs of the invention is via a gene gun.

The DNA can be injected into the animal as naked DNA, with lipofection reagents, with carriers, or with any composition known to enhance the uptake of DNA by the cell, as described for example in U.S. Pat. Nos. 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all of which have been hereby incorporated by reference. A carrier includes any other active ingredient required for the working of the vaccine composition, any solvent, dispersion media, vehicle, coating, diluent, anti-bacterial or anti-fungal agent, buffer, isotonic solution, absorption delaying agent, colloid, suspension medium, etc.

The effective amount of the DNA construct(s) to be injected varies depending on, for example, the type of antigen and its level of expression (needs to be standardized for each antigen), the route of administration, size (body weight of the host), form of the encoded antigen, that is, whether the antigen is a cytoplasmic, membrane bound or a secreted protein, etc. The effective amount or dosage of a DNA construct to be injected into an animal is that amount of DNA that effectively achieves optimal immunization or immunotherapeutic treatment for any administered antigen. For example, an injection dosage of approx. 1 μ g of DNA per Helios gene gun bullet per animal was found to be optimal for some antigens used in this invention but any other suitable dosages may also be used. The DNA immunization may be done repeatedly, according to a suitable schedule, depending on the type of disease being treated, the dosage required to maintain a protective level of immunity, etc. as can be routinely determined by one skilled in the art.

Besides coding for structural DNA sequences of interest, expression cassettes may further contain sequences encoding for secretion leader sequences to ensure secretion of the encoded antigen, domains that improve protein solubility and/or protein folding to enhance uptake of the antigen by antigen presenting cells (e.g. the 46 residue COMP domain), epitopes for T-helper-independent B-cell activation, etc.

The present invention further provides nucleic acid sequences that encode for proteins, polypeptides or peptide sequences for rabbit GMCSF, which are useful as an adjuvants.

Expression of GMCSF may be under the control of a constitutively active promoter, a tissue specific promoter or an inducible promoter.

It is also contemplated that a given nucleic acid sequence for rabbit GMCSF may be represented by natural variants that have slightly different nucleic acid sequences but,

5 nonetheless, encode the same protein. Furthermore, the term functionally equivalent codon is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine (Table 1), and also refers to codons that encode biologically equivalent amino acids, as discussed herein.

Table 1

Amino Acids		Codons	
Alanine	Ala	A	GCA GCC GCG GCU
Cysteine	Cys	C	UGC UGU
Aspartic acid	Asp	D	GAC GAU
Glutamic acid	Glu	E	GAA GAG
Phenylalanine	Phe	F	UUC UUU
Glycine	Gly	G	GGA GGC GGG GGU
Histidine	His	H	CAC CAU
Isoleucine	Ile	I	AUA AUC AUU
Lysine	Lys	K	AAA AAG
Leucine	Leu	L	UUA UUG CUA CUC CUG CUU
Methionine	Met	M	AUG
Asparagine	Asn	N	AAC AAU
Proline	Pro	P	CCA CCC CCG CCU
Glutamine	Gln	Q	CAA CAG
Arginine	Arg	R	AGA AGG CGA CGC CGG CGU
Serine	Ser	S	AGC AGU UCA UCC UCG UCU
Threonine	Thr	T	ACA ACC ACG ACU
Valine	Val	V	GUA GUC GUG GUU
Tryptophan	Trp	W	UGG
Tyrosine	Tyr	Y	UAC UAU

10

The DNA segments used in the present invention encompass biologically functional equivalent modified polypeptides and peptides. Such sequences may arise as a consequence of codon redundancy and functional equivalency that are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes
15 in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by human may be introduced through the application of site-directed mutagenesis techniques, e.g., to introduce improvements to the

antigenicity of the protein, to reduce toxicity effects of the protein in vivo to a subject given the protein, or to increase the efficacy of any treatment involving the protein.

Allowing for the degeneracy of the genetic code (Table 1), the invention encompasses sequences that have at least about 50%, usually at least about 60%, more usually about 70%,
5 most usually about 80%, preferably at least about 90% and most preferably about 95% of nucleotides that are identical to the nucleotides of SEQ ID NO: 2.

The term biologically functional equivalent is well understood in the art and is further defined in detail herein. Accordingly, sequences that have between about 70% and about 80%; or
10 more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of amino acids that are identical or functionally equivalent to the amino acids of a rabbit GMCSF polypeptide, provided the biological activity of the protein is maintained.

The term functionally equivalent codon is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also refers to codons that
15 encode biologically equivalent amino acids (Table 1).

The following is a discussion based upon changing of the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions
20 of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid substitutions can be made in a protein sequence, and in its underlying DNA coding sequence, and nevertheless produce a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the DNA sequences of genes without appreciable loss of
25 their biological utility or activity, as discussed below. Table 1 shows the codons that encode particular amino acids.

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte & Doolittle, 1982). It is accepted that the relative
30 hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0. \pm .1); glutamate (+3.0. \pm .1); serine (+0.3); asparagine (+0.2) glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5. \pm .1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still produce a biologically equivalent and immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within \pm .2 is preferred, those that are within \pm .1 are particularly preferred, and those within \pm .0.5 are even more particularly preferred.

As outlined herein, amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take into consideration the various foregoing characteristics are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

Another embodiment for the preparation of polypeptides according to the invention is the use of peptide mimetics. Mimetics are peptide-containing molecules that mimic elements of protein secondary structure (Johnson 1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions, such as those of antibody and antigen. A peptide mimetic is expected to permit molecular interactions similar to the natural molecule. These principles may be used, in conjunction with the principles outline above, to engineer second generation molecules having many of the natural properties of adjuvants with altered and improved characteristics.

Thus, variant nucleic acid sequences that encode for rabbit GMCSF and functionally equivalent polypeptides of rabbit GMCSF are useful as adjuvants in this invention.

In another aspect of this invention, the animals to whom the DNA constructs of the invention can be administered include, but are not limited to, mammals (e.g. humans, non-human

primates, rodents (e.g. mice and rats), non-rodents (e.g. rabbits, pigs, sheep, goats, cows, pigs, horses and donkeys), and birds (e.g., chickens, turkeys, ducks, geese and the like). The animals to whom the DNA constructs of the invention can be administered include 'gene converting animals', that is, animals that create antibody diversity substantially by gene conversion and/or somatic hypermutation (for e.g. rabbits, birds, cows, swine, etc.), and animals where antibody rearrangement stops early in life, that is, typically, within the first month of life (for e.g. rabbits, birds, sheep, goats, cattle, swine, horses, etc.)

Further, animals to whom the DNA constructs of the invention can be administered also include any of the non-human animal described above, further carrying a transgene encoding an exogenous immunoglobulin translocus, preferably, a human or humanized immunoglobulin heavy chain and/or immunoglobulin light chain sequence or parts thereof. The transgene locus can be either in the germline configuration or in a rearranged form. Since the transgenes encode for human or humanized immunoglobulins or parts thereof, it results in the generation of humanized antibodies. Thus, for example, using the recombinase mediated DNA immunization methods described above, antibodies, including humanized antibodies, can be generated in target non-human animals using the rabbit GMCSF adjuvant described in this invention.

The invention is further illustrated by, but by no means limited to, certain embodiments referenced in the examples below. One skilled in the art will understand that various modifications of the present invention can be performed without substantial change in the way the invention works. All of such modifications are specifically intended to be within the scope of the invention claimed herein.

Example 1

Cloning of Rabbit GMCSF

Peritoneal macrophages from ZIKA rabbits were harvested by lavage of the peritoneal cavity with 30-60ml PBS / 2% FCS (Gibco; PET 10270098), and washed twice. The cells were counted and plated in one well of a 24 well plate with a density of $1-3 \times 10^5$ cells/well in DMEM / 10% FCS and stimulated for 5hrs with 1 μ g/ml LPS E.coli O111:B4 (Sigma; L2630) in a humidified 5%CO₂ incubator at 37°C. Cells were harvested and total RNA was isolated with QIA_{Amp} RNA-Mini-Kit (Qiagen) according to the manufactures instructions.

3-6 μ l total RNA was reverse transcribed with the 3'-RACE CDS Primer A (5'-AAGCAGTGGTATCAACGCAGAGTAC(T)₃₀VN-3') (SEQ ID NO: 3) using the BD SMART RACE cDNA Amplification Kit (BD Biosciences) according to the manufactures protocol.

Rabbit GMCSF was PCR amplified from first strand cDNA with the primer pair *GMCSFup3* (5'-aaggctaaggtcctgaggagg-3') (SEQ ID NO: 4) and 10x universal primer A mix (mixture of 5'-CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-3' (SEQ ID NO: 5) and 5'-CTAATACGACTCACTATAGGGC-3') (SEQ ID NO: 6) using the Eppendorf Triple Master polymerase with High Fidelity buffer. PCR conditions were: Denaturation at 94°C for 50s, annealing at 60°C for 50s and extension at 72°C for 50s, 35 cycles. PCR products were analysed by electrophoresis in 1.2 % agarose gels. Specific bands were cut and extracted using the Gene Clean Turbo gel extraction Kit (Bio101) and cloned into TOPO TA Cloning Vector (Invitrogen) and sequenced (Agowa).

Example 2

Generation of anti-CD20 antibodies in rabbits by genetic immunization

Messenger RNA (mRNA) from rabbit LPS-stimulated peritoneal macrophages and lymphocytes is isolated and reverse transcribed. Rabbit GMCSF and Flt3L cDNAs are amplified by PCR. Subsequently, the cDNAs are cloned into an expression plasmid. A cDNA encoding the soluble part of human CD20 is synthesized and cloned into the same expression plasmid. The final construct is shown in Figure 1. Plasmid DNA is purified and mixed with an equal amount of a plasmid encoding C31 integrase. Plasmid DNA (about 1 µg/bullet) is coated on Helios gene gun bullets according to the manufacturer's instructions. Rabbits are mildly anesthetized and shot in each ear on day 0 and day 14. Blood is collected and allowed to coagulate. Sera are collected by centrifugation. Anti-CD20 antibodies are detected by flow cytometry using human peripheral blood lymphocytes. A comparison of animals immunized with and without rabbit GMCSF shows that administration of rabbit GMCSF increases the immune response significantly.

WHAT IS CLAIMED IS:

- 1 1. A rabbit GMCSF polypeptide of SEQ ID NO: 1.
- 1 2. A chimeric molecule comprising the polypeptide of claim 1 fused to a
2 heterologous amino acid sequence.
- 1 3. The chimeric molecule of claim 2 wherein said heterologous amino acid sequence
2 is an epitope sequence.
- 1 4. The chimeric molecule of claim 2 wherein said heterologous amino acid sequence
2 is an immunoglobulin sequence.
- 1 5. The chimeric molecule of claim 4 wherein said immunoglobulin sequence is an
2 Fc region of an immunoglobulin.
- 1 6. A nucleotide sequence comprising a nucleotide sequence encoding the rabbit
2 GMCSF polypeptide of claim 1.
- 1 7. A vector or expression cassette comprising the nucleotide sequence of claim 6.
- 1 8. An isolated host cell transformed with the nucleic acid of claim 6.
- 1 9. A method for immunizing or vaccinating an animal, said method comprising:
2 (i) administering at least one DNA construct comprising at least one expression
3 cassette that encodes for an antigen, and a first recombination site;
4 (ii) stimulating the immune system of said animal by administering at least one
5 adjuvant to said animal; and,
6 (iii) administering a recombinase that mediates the integration of said expression
7 cassette into the genome of said animal comprising a second recombination site,
8 wherein, said antigen is expressed.
- 1 10. The method of claim 9 wherein said adjuvant is introduced as a polypeptide.

1 11. The method of claim 9 wherein the administration of the adjuvant comprises
2 introducing to said animal: (i) said adjuvant as a DNA construct comprising an expression
3 cassette that encodes for said adjuvant, and, a first recombination site; and, (ii) a recombinase
4 that mediates the integration of said expression cassette into the genome of said animal
5 comprising a second recombination site, wherein, said adjuvant is expressed.

1 12. The method of claim 9 wherein said antigen(s) is/are selected from the group
2 consisting of viral, bacterial, fungal, protozoal antigens and antigens associated with diseases
3 like infection, inflammation, cancer, asthma/allergy, autoimmune diseases, multiple sclerosis,
4 sepsis/toxic shock, rheumatoid arthritis, allograft rejections, psoriasis, etc.

1 13. The method of claim 9 wherein said antigen is CD20.

1 14. The method of claim 11 wherein said adjuvant(s) is/are selected from the group
2 consisting of GMCSF, Flt3L, interleukins like IL-1 α and β , IL-2, IL-12, IL-15, IL-18, IL-4, IL-
3 5, IL-6, IL-10, TNF- α , TNF- β , IFN- γ , etc. and co-stimulatory molecules like TCA3, CD80
4 (B7.1), CD86 (B7.2), CD40 ligand (CD154), MCP-1, MIP-1 α , β , RANTES, etc.

1 15. The method of claim 11 wherein said adjuvant is the rabbit GMCSF of SEQ ID
2 NO: 1.

1 16. The method of claim 11 wherein said antigen-encoding expression cassette and
2 said adjuvant-encoding expression cassette are part of one DNA construct.

1 17. The method of claim 11 wherein said antigen-encoding expression cassette and
2 said adjuvant-encoding expression cassette are on separate DNA constructs.

1 18. The method of claim 9 or 11 wherein said recombinase is administered as a
2 polypeptide.

1 19. The method of claim 9 or 11 wherein said recombinase is administered as a
2 messenger RNA molecule encoding said recombinase.

- 1 20. The method of claim 9 or 11 wherein said recombinase is administered as a DNA
2 construct comprising an expression cassette encoding said recombinase.
- 1 21. The method of claim 9 or 11 wherein said recombinase is a site-specific
2 recombinase expressed by a phage.
- 1 22. The method of claim 21 wherein said recombinase is selected from the group
2 consisting of ϕ C31, phage R4 and TP901-1.
- 1 23. The method of claim 21 wherein said site specific recombinase is selected from
2 the group consisting of a Cre-recombinase, a Cre-like recombinase, a Flp recombinase and an R
3 recombinase.
- 1 24. The method of claim 9 or 11 wherein said recombinase is a transposase or a
2 retrotransposase.
- 1 25. The method of claim 24, wherein said transposase is selected from the group
2 consisting of AC7, Tn5, Tn916, Tn951, Tn1721, Tn2410, Tn1681, Tn1, Tn2, Tn3, Tn4, Tn5,
3 Tn6, Tn9, Tn10, Tn30, Tn101, Tn903, Tn501, Tn1000, Tn1681, tn2901, AC transposons, Mp
4 transposons, Spm transposons, En transposons, Dotted transposons, Mu transposons, Ds
5 transposons, En transposons, and I transposons.
- 1 26. The method of claim 24, wherein said transposase is a eukaryotic transposase.
- 1 27. The method of claim 9 or 11 wherein said first and second recombination sites
2 share at least 90% sequence identity.
- 1 28. The method of claim 9 or 11 wherein said first and second recombination sites
2 share less than 90% sequence identity.

1 29. The method of claim 9 or 11 wherein said first recombination site comprises a
2 bacterial genomic recombination site and said second recombination site comprises a phage
3 recombination site.

1 30. The method of claim 29 wherein said bacterial genomic recombination site is attB
2 and said phage recombination site is attP.

1 31. The method of claim 29, wherein said first recombination site comprises an attB
2 site, and said second recombination site comprises a pseudo-attP site.

1 32. The method of claim 29, wherein said first recombination site comprises a
2 pseudo-attB site, and said second recombination site comprises an attP site.

1 33. The method of claim 9 or 11, wherein said recombinase-mediated recombination
2 results in a site that is no longer a substrate for the recombinase.

1 34. The method of claim 9 or 11 wherein said DNA construct(s) is/are circular.

1 35. The method of claim 9 or 11 wherein said DNA construct(s) is/are linear.

1 36. The method of claim 9 wherein said animal is non-human mammal.

1 37. The method of claim 36 wherein said non-human mammal is a rabbit.

1 38. The method of claim 9 wherein said animal is a human.

1 39. A method for producing antibodies in an animal, comprising:
2 (i) administering at least one DNA expression cassette encoding an antigen, a
3 recombination site, and a recombinase that mediates the integration of said DNA expression
4 cassette into the genome of said animal;
5 (ii) optionally administering at least one adjuvant;
6 (iii) harvesting a serum sample after several days from said animal;

7 (iv) identifying and optionally, purifying antibodies to said administered
8 antigen(s) from said serum sample.

1 40. The method of claim 39 wherein said adjuvant is introduced as a polypeptide.

1 41. The method of claim 39 wherein said adjuvant is introduced as a nucleic acid
2 comprising an expression cassette encoding said adjuvant, a recombination site and a
3 recombinase that mediates the integration of said adjuvant encoding-DNA expression cassette
4 into the genome of said animal.

1 42. The method of claim 39 wherein said animal is a human.

1 43. The method of claim 39 wherein said animal is a non-human mammal.

1 44. The method of claim 39 wherein said animal is a non-human transgenic animal
2 carrying an exogenous immunoglobulin translocus.

1 45. The method of claim 44 wherein said exogenous immunoglobulin translocus is a
2 human or humanized immunoglobulin heavy and/or light chain sequence.

1 46. The method of claim 44 wherein said non-human transgenic animal is a gene
2 converting animal.

1 47. The method of claim 44 wherein said non-human transgenic animal is selected
2 from the group consisting of rodents, rabbits, birds including chickens, turkeys, ducks and geese.

1 48. The method of claim 43 wherein said non-human mammal is a rabbit.

1 49. The method of claim 39 wherein said antigen is selected from the group
2 consisting of viral, bacterial, fungal, protozoal antigens and antigens associated with diseases
3 like cancer, asthma/allergy, autoimmune diseases, multiple sclerosis, inflammation/sepsis/toxic
4 shock, rheumatoid arthritis, allograft rejections, psoriasis, etc.

1 50. The method of claim 49 wherein said antigen is CD20.

1 51. The method of claim 39 wherein said adjuvant is selected from the group
2 consisting of GMCSF, Flt3L, interleukins like IL-1 α and β , IL-2, IL-12, IL-15, IL-18, IL-4, IL-
3 5, IL-6, IL-10, TNF- α , TNF- β , IFN- γ , etc. and co-stimulatory molecules like TCA3, CD80
4 (B7.1), CD86 (B7.2), CD40 ligand (CD154), MCP-1, MIP-1 α , β , RANTES, etc.

1 52. The method of claim 39 wherein said adjuvant is a rabbit GMCSF of SEQ ID NO:
2 1.

Figure 1 (SEQ ID NO: 1)

MWLQNLFLLGSVVCTISAPTHQPNTVSQPLKHVDAlKEARIILSRSNDSAAVPGEMVEV
VSEMFDPQKPTCLQTRLELYKQGLRGSRLRLSSTLTLMASHYKQNCPPPTPETSCETEFITF
KSFKENLKCFLFVIPFNCWEPVQK

Figure 2 (SEQ ID NO: 2)

AAGGCTAAGGTCCTGAGGAGGATGTGGTTGCAGAACCTGTTCCCTCCTAGGCAGTGTG
GTCTGCACCATCTCTGCACCCACCCACCAGCCCAACACTGTCAGCCAGCCCTTGAAG
CATGTGGATGCCATCAAGGAGGCCCGGATCATCCTGAGCCGCAGTAACGATTCTGC
CGCTGTGCCGGGCGAAATGGTAGAAGTCGTCTCTGAAATGTTTGATCCTCAGAAACC
AACTTGCCTGCAGACCCGCCTGGAAGTGTACAAGCAAGGCCTGCGGGGCAGCCTGG
AGCGGCTCTCGAGTACCCTGACTTTGATGGCCAGCCACTACAAGCAAAACTGTCCCC
CAACCCCGGAAACTTCCTGTGAGACCGAGTTTATCACCTTCAAAGTTTCAAAGAGA
ACCTGAAGTGCTTTCTGTTTGTGTCATCCCCCTTTAACTGCTGGGAGCCAGTCCAGAAGT
GAGGAAGCGCAGGCTAGCCAGGCCAGCCCTGGTTGTTGACCTCAGAGACTACTGCT
CTCCCACCCAAAAGAGCCAAAAACTCAGGATCTTCGTGTTGGAGGGACCAAGGGGC
CACTGTGGGGACAGCATGGACCTGCCCTGGACCACACTGACCCAGTTATGGACCTG
CCCTGGACCACACTGACCCAGTTATGGACCTGCCC





Figure 4

39691-0013 PCT Saved 9 Dec 2005.txt

SEQUENCE LISTING

<110> THERAPEUTIC HUMAN POLYCLONALS, INC.
BUELOW, ROLAND
PLATZER, JOSEF

<120> IMPROVED DNA IMMUNIZATION WITH
RECOMBINASE/TRANSPOSASE

<130> 39691-0013 PCT

<140> To Be Assigned

<141> Herewith

<150> US 60/636,361

<151> 2004-12-14

<160> 19

<170> FastSEQ for windows version 4.0

<210> 1

<211> 144

<212> PRT

<213> Oryctolagus cuniculus

<400> 1

Met	Trp	Leu	Gln	Asn	Leu	Phe	Leu	Leu	Gly	Ser	Val	Val	Cys	Thr	Ile
1				5					10					15	
Ser	Ala	Pro	Thr	His	Gln	Pro	Asn	Thr	Val	Ser	Gln	Pro	Leu	Lys	His
			20					25					30		
Val	Asp	Ala	Ile	Lys	Glu	Ala	Arg	Ile	Ile	Leu	Ser	Arg	Ser	Asn	Asp
		35					40					45			
Ser	Ala	Ala	Val	Pro	Gly	Glu	Met	Val	Glu	Val	Val	Ser	Glu	Met	Phe
	50					55					60				
Asp	Pro	Gln	Lys	Pro	Thr	Cys	Leu	Gln	Thr	Arg	Leu	Glu	Leu	Tyr	Lys
65					70					75				80	
Gln	Gly	Leu	Arg	Gly	Ser	Leu	Glu	Arg	Leu	Ser	Ser	Thr	Leu	Thr	Leu
			85						90					95	
Met	Ala	Ser	His	Tyr	Lys	Gln	Asn	Cys	Pro	Pro	Thr	Pro	Glu	Thr	Ser
			100					105					110		
Cys	Glu	Thr	Glu	Phe	Ile	Thr	Phe	Lys	Ser	Phe	Lys	Glu	Asn	Leu	Lys
		115					120					125			
Cys	Phe	Leu	Phe	Val	Ile	Pro	Phe	Asn	Cys	Trp	Glu	Pro	Val	Gln	Lys
		130					135				140				

<210> 2

<211> 657

<212> DNA

<213> Oryctolagus cuniculus

<400> 2

aaggctaagg	tcctgaggag	gatgtggttg	cagaacctgt	tcctcctagg	cagtgtggtc	60
tgcaccatct	ctgcacccac	ccaccagccc	aacactgtca	gccagccctt	gaagcatgtg	120
gatgccatca	aggaggcccg	gatcatcctg	agccgcagta	acgattctgc	cgctgtgccg	180
ggcgaaatgg	tagaagtcgt	ctctgaaatg	tttgatcctc	agaaaccaac	ttgcctgcag	240
acccgcctgg	aactgtacaa	gcaaggcctg	cggggcagcc	tggagcggct	ctcgagtacc	300
ctgactttga	tggccagcca	ctacaagcaa	aactgtcccc	caacccccga	aacttcctgt	360
gagaccgagt	ttatcacctt	caaaagtttc	aaagagaacc	tgaagtgcct	tctgtttgtc	420
atccccctta	actgctggga	gccagtcag	aagtgaggaa	gcgcaggcta	gccaggccag	480
ccctggttgt	tgacctcaga	gactactgct	ctccaccca	aaagagccaa	aaactcagga	540
tcttcgtgtt	ggagggacca	aggggccact	gtggggacag	catggacctg	ccctggacca	600
cactgacca	gttatggacc	tgccctggac	cacactgacc	cagttatgga	cctgccc	657

<210> 3

<211> 26

39691-0013 PCT Saved 9 Dec 2005.txt

<212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 3
 aagcagtgggt atcaacgcag agtact

26

<210> 4
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 4
 aaggctaagg tcctgaggag g

21

<210> 5
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 5
 ctaatacgac tcactatagg gcaagcagtg gtatcaacgc agagt

45

<210> 6
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 6
 ctaatacgac tcactatagg gc

22

<210> 7
 <211> 144
 <212> PRT
 <213> Homo sapien

<400> 7
 Met Trp Leu Gln Ser Leu Leu Leu Leu Gly Thr Val Ala Cys Ser Ile
 1 5 10 15
 Ser Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr Gln Pro Trp Glu His
 20 25 30
 Val Asn Ala Ile Gln Glu Ala Arg Arg Leu Leu Asn Leu Ser Arg Asp
 35 40 45
 Thr Ala Ala Glu Met Asn Glu Thr Val Glu Val Ile Ser Glu Met Phe
 50 55 60
 Asp Leu Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Glu Leu Tyr Lys
 65 70 75 80
 Gln Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met
 85 90 95
 Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr Ser
 100 105 110
 Cys Ala Thr Gln Ile Ile Thr Phe Glu Ser Phe Lys Glu Asn Leu Lys
 115 120 125

39691-0013 PCT Saved 9 Dec 2005.txt

Asp Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro Val Gln Glu
 130 135 140

<210> 8
 <211> 141
 <212> PRT
 <213> Mus musculus

<400> 8
 Met Trp Leu Gln Asn Leu Leu Phe Leu Gly Ile Val Val Tyr Ser Leu
 1 5 10 15
 Ser Ala Pro Thr Arg Ser Pro Ile Thr Val Thr Arg Pro Trp Lys His
 20 25 30
 Val Glu Ala Ile Lys Glu Ala Leu Asn Leu Leu Asp Asp Met Pro Val
 35 40 45
 Thr Leu Asn Glu Glu Val Glu Val Val Ser Asn Glu Phe Ser Phe Lys
 50 55 60
 Lys Leu Thr Cys Val Gln Thr Arg Leu Lys Ile Phe Glu Gln Gly Leu
 65 70 75 80
 Arg Gly Asn Phe Thr Lys Leu Lys Gly Ala Leu Asn Met Thr Ala Ser
 85 90 95
 Tyr Tyr Gln Thr Tyr Cys Pro Pro Thr Pro Glu Thr Asp Cys Glu Thr
 100 105 110
 Gln Val Thr Thr Tyr Ala Asp Phe Ile Asp Ser Leu Lys Thr Phe Leu
 115 120 125
 Thr Asp Ile Pro Phe Glu Cys Lys Lys Pro Val Gln Lys
 130 135 140

<210> 9
 <211> 144
 <212> PRT
 <213> Felis

<400> 9
 Met Trp Leu Gln Asn Leu Leu Phe Leu Asn Thr Val Val Cys Ser Ile
 1 5 10 15
 Ser Ala Pro Thr Ser Ser Pro Ser Ser Val Thr Arg Pro Trp Gln His
 20 25 30
 Val Asp Ala Met Lys Glu Ala Leu Ser Leu Leu Asn Asn Ser Ser Glu
 35 40 45
 Ile Thr Ala Val Met Asn Glu Thr Val Glu Val Val Ser Glu Met Phe
 50 55 60
 Asp Pro Glu Glu Pro Lys Cys Leu Gln Thr His Leu Lys Leu Tyr Glu
 65 70 75 80
 Gln Gly Leu Arg Gly Ser Leu Ile Ser Leu Lys Glu Pro Leu Arg Met
 85 90 95
 Met Ala Asn His Tyr Lys Gln His Cys Pro Leu Thr Pro Glu Thr Pro
 100 105 110
 Cys Glu Thr Gln Thr Ile Thr Phe Lys Asn Phe Lys Glu Lys Leu Lys
 115 120 125
 Asp Phe Leu Phe Asn Asn Pro Phe Asp Cys Trp Gly Pro Asp Gln Lys
 130 135 140

<210> 10
 <211> 146
 <212> PRT
 <213> Equus

<400> 10
 Met Trp Leu Gln Asn Leu Leu Leu Leu Gly Thr Val Val Tyr Ser Met
 1 5 10 15
 Pro Ala Pro Thr Arg Gln Pro Ser Pro Val Thr Arg Pro Trp Gln His
 20 25 30
 Val Asp Ala Ile Lys Glu Ala Leu Ser Leu Leu Asn Asn Ser Ser Asp
 35 40 45

39691-0013 PCT Saved 9 Dec 2005.txt

Thr Ala Ala Ile Met Asn Glu Thr Val Glu Val Val Ser Glu Thr Phe
 50 55 60
 Asp Ala Glu Glu Leu Thr Cys Leu Gln Thr Arg Leu Lys Leu Tyr Lys
 65 70 75 80
 Gln Gly Leu Arg Gly Ser Leu Ile Lys Leu Glu Gly Pro Leu Thr Met
 85 90 95
 Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Leu Glu Thr Ser
 100 105 110
 Cys Ala Thr Gln Met Ile Thr Phe Lys Ser Phe Lys Lys Asn Leu Lys
 115 120 125
 Asp Phe Leu Phe Glu Ile Pro Phe Asp Cys Trp Lys Pro Ala Gln Lys
 130 135 140
 Leu Glu
 145

<210> 11
 <211> 144
 <212> PRT
 <213> Macaca

<400> 11
 Met Trp Leu Gln Gly Leu Leu Leu Leu Gly Thr Val Ala Cys Ser Ile
 1 5 10 15
 Ser Ala Pro Ala Arg Ser Pro Ser Pro Gly Thr Gln Pro Trp Glu His
 20 25 30
 Val Asn Ala Ile Gln Glu Ala Arg Arg Leu Leu Asn Leu Ser Arg Asp
 35 40 45
 Thr Ala Ala Glu Met Asn Lys Thr Val Glu Val Val Ser Glu Met Phe
 50 55 60
 Asp Leu Gln Glu Pro Ser Cys Leu Gln Thr Arg Leu Glu Leu Tyr Lys
 65 70 75 80
 Gln Gly Leu Gln Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met
 85 90 95
 Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr Ser
 100 105 110
 Cys Ala Thr Gln Ile Ile Thr Phe Gln Ser Phe Lys Glu Asn Leu Lys
 115 120 125
 Asp Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro Val Gln Glu
 130 135 140

<210> 12
 <211> 144
 <212> PRT
 <213> Sus

<400> 12
 Met Trp Leu Gln Asn Leu Leu Leu Leu Gly Thr Val Val Cys Ser Ile
 1 5 10 15
 Ser Ala Pro Thr Arg Pro Pro Ser Pro Val Thr Arg Pro Trp Gln His
 20 25 30
 Val Asp Ala Ile Lys Glu Ala Leu Ser Leu Leu Asn Asn Ser Asn Asp
 35 40 45
 Thr Ala Ala Val Met Asn Glu Thr Val Asp Val Val Cys Glu Met Phe
 50 55 60
 Asp Pro Gln Glu Pro Thr Cys Val Gln Thr Arg Leu Asn Leu Tyr Lys
 65 70 75 80
 Gln Gly Leu Arg Gly Ser Leu Thr Arg Leu Lys Ser Pro Leu Thr Leu
 85 90 95
 Leu Ala Lys His Tyr Glu Gln His Cys Pro Leu Thr Glu Glu Thr Ser
 100 105 110
 Cys Glu Thr Gln Ser Ile Thr Phe Lys Ser Phe Lys Asp Ser Leu Asn
 115 120 125
 Lys Phe Leu Phe Thr Ile Pro Phe Asp Cys Trp Gly Pro Val Lys Lys
 130 135 140

39691-0013 PCT Saved 9 Dec 2005.txt

<210> 13
 <211> 144
 <212> PRT
 <213> Papio

<400> 13
 Met Trp Leu Gln Gly Leu Leu Leu Leu Gly Thr Val Ala Cys Ser Ile
 1 5 10 15
 Ser Ala Pro Ala Arg Leu Pro Ser Pro Gly Met Gln Pro Trp Glu His
 20 25 30
 Val Asn Ala Ile Gln Glu Ala Arg Leu Leu Asn Leu Ser Arg Asp
 35 40 45
 Thr Ala Ala Glu Met Asn Lys Thr Val Glu Val Val Ser Glu Met Phe
 50 55 60
 Asp Leu Gln Glu Pro Ser Cys Val Gln Thr Arg Leu Glu Leu Tyr Lys
 65 70 75 80
 Gln Gly Leu Gln Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met
 85 90 95
 Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr Ser
 100 105 110
 Cys Ala Thr Gln Ile Ile Thr Phe Gln Ser Phe Lys Glu Asp Leu Lys
 115 120 125
 Asp Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro Val Gln Glu
 130 135 140

<210> 14
 <211> 143
 <212> PRT
 <213> Bubalus

<400> 14
 Met Trp Leu Gln Asn Leu Leu Leu Leu Gly Thr Val Val Cys Ser Phe
 1 5 10 15
 Ser Ala Pro Thr Arg Pro Pro Ser Thr Val Thr Arg Pro Trp Gln His
 20 25 30
 Val Asp Ala Ile Lys Glu Ala Leu Ser Leu Leu Asn Gln Ser Ser Glu
 35 40 45
 Pro Asp Ala Gly Met Asn Asp Thr Glu Val Val Ser Glu Met Phe Asp
 50 55 60
 Ala Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Lys Leu Tyr Lys Lys
 65 70 75 80
 Gly Leu Gln Gly Ser Leu Thr Ser Leu Met Gly Ser Leu Thr Met Met
 85 90 95
 Ala Thr His Tyr Glu Lys His Cys Pro Pro Thr Pro Glu Thr Ser Cys
 100 105 110
 Gly Thr Gln Phe Ile Thr Phe Lys Ser Phe Lys Glu Asp Leu Lys Glu
 115 120 125
 Phe Leu Phe Ile Ile Pro Phe Asp Cys Trp Glu Pro Ala Gln Lys
 130 135 140

<210> 15
 <211> 144
 <212> PRT
 <213> Cervus

<400> 15
 Met Trp Leu Gln Asn Leu Leu Leu Leu Gly Thr Val Val Cys Ser Phe
 1 5 10 15
 Ser Ala Pro Thr Arg Pro Ala Ser Pro Val Thr Arg Pro Trp Gln His
 20 25 30
 Val Asp Ala Ile Lys Glu Ala Leu Ser Leu Leu Asn His Ser Ser Asp
 35 40 45
 Thr Ala Ala Val Met Asn Glu Thr Val Glu Val Val Ser Glu Pro Phe
 50 55 60
 Asp Ser Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Lys Leu Tyr Lys
 65 70 75 80

39691-0013 PCT Saved 9 Dec 2005.txt

Gln Gly Leu Arg Gly Ser Leu Thr Ser Leu Ser Gly Ser Leu Thr Met
 85 90 95
 Met Ala Arg His Tyr Glu Gln His Cys Pro Pro Thr Gln Glu Thr Ser
 100 105 110
 Cys Glu Thr Gln Thr Ile Thr Phe Lys Ser Phe Lys Glu Asn Leu Lys
 115 120 125
 Asp Phe Leu Phe Ile Ile Pro Phe Asp Cys Trp Glu Pro Ala Gln Lys
 130 135 140

<210> 16
 <211> 145
 <212> PRT
 <213> Meriones

<400> 16
 Met Trp Leu Gln Asn Leu Leu Phe Leu Ser Ile Val Val Tyr Ser Phe
 1 5 10 15
 Ser Ala Pro Thr His Ser Pro Ile Thr Val Thr Gln Pro Trp Lys His
 20 25 30
 Val Asp Ala Ile Lys Glu Ala Leu Ser Leu Leu Glu Lys Met Leu Lys
 35 40 45
 Ile Pro Ala Met Leu Asp Glu Asp Asp Val Asp Ile Val Ser Glu Glu
 50 55 60
 Phe Ser Val Gln Arg Pro Thr Cys Leu Gln Lys Arg Leu Lys Val Tyr
 65 70 75 80
 Glu Gln Gly Leu Arg Gly Asn Phe Thr Arg Phe Arg Gly Thr Leu Ala
 85 90 95
 Met Ile Ala Arg His Tyr Gln Lys Tyr Cys Pro Pro Thr Pro Glu Asp
 100 105 110
 Glu Cys Glu Thr Glu Val Thr Thr Phe Gly Asp Phe Ile Asp Ser Leu
 115 120 125
 Lys Asn Phe Leu Phe Asp Ile Pro Phe Asp Cys Trp Glu Pro Val Gln
 130 135 140
 Glu
 145

<210> 17
 <211> 145
 <212> PRT
 <213> Cavia

<400> 17
 Met Trp Leu Gln Asn Leu Leu Leu Leu Gly Thr Val Val Cys Ser Ile
 1 5 10 15
 Cys Ala Pro Thr Asp Leu Leu Ser Pro Val Thr Gln Ser Trp Lys His
 20 25 30
 Val Asp Ala Thr Ile Asn Glu Ala Leu Ser Leu Leu Asn His Thr Ser
 35 40 45
 Asp Pro Ala Ala Val Met Asn Glu Thr Val Glu Val Val Tyr Asp Gln
 50 55 60
 Phe Glu Pro Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Ala Leu Phe
 65 70 75 80
 Met Lys Gly Leu Arg Gly Asn Leu Thr Arg Leu Glu Gly Ser Leu Thr
 85 90 95
 Leu Met Ala Asn Phe Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr
 100 105 110
 Ser Cys Met Thr Gln Ile Ile Thr Phe Lys Ser Phe Lys Glu Asn Leu
 115 120 125
 Lys Arg Phe Leu Phe Ala Ile Pro Phe Asp Cys Trp Glu Pro Val Gln
 130 135 140
 Lys
 145

<210> 18
 <211> 141

39691-0013 PCT Saved 9 Dec 2005.txt

<212> PRT

<213> Sigmodon

<400> 18

```

Met Trp Leu Gln Phe Leu Leu Phe Leu Gly Ile Val Val Cys Ser Phe
 1      5      10      15
Ser Ala Pro Thr Arg Ser Pro Ala Ser Val Thr Arg Pro Trp Lys His
      20      25      30
Val Asp Ala Ile Lys Glu Ala Leu Ser Leu Leu Asn Asp Met Pro Ala
      35      40      45
Met Glu Asn Glu Asp Val Asp Ile Val Ser Lys Glu Phe Ser Ile Gln
      50      55      60
Arg Pro Thr Cys Val Gln Thr Arg Leu Lys Val Tyr Gln Gln Gly Leu
65      70      75      80
Gln Gly Asn Phe Thr Lys Leu Lys Gly Ala Leu Asn Met Met Ala Ser
      85      90      95
His Tyr Gln Lys Asn Cys Pro Pro Thr Pro Glu Ile Asp Cys Glu Thr
      100      105      110
Gln Val Thr Thr Phe Glu Asp Phe Ile Asp Asn Leu Lys Gly Phe Leu
      115      120      125
Phe Asp Ile Pro Phe Asp Cys Trp Lys Pro Val Gln Lys
      130      135      140

```

<210> 19

<211> 90

<212> PRT

<213> Peromyscus

<400> 19

```

Met Trp Leu Lys Ile Leu Leu Phe Leu Gly Ile Val Val Cys Ser Phe
 1      5      10      15
Ser Ala Pro Thr Arg Ser Pro Ala Pro Val Thr Gln Pro Trp Asn His
      20      25      30
Val Glu Ala Ile Lys Glu Ala Leu Ile Leu Leu Asp Asn Ala Pro Asp
      35      40      45
Ile Val Ser Glu Asp Glu Asp Val Glu Ile Val Ser Glu Glu Phe Ser
      50      55      60
Val Gln Lys Cys Val Gln Glu Arg Leu Gln Leu Tyr Glu Lys Gly Leu
65      70      75      80
Arg Gly Asn Leu Thr Lys Leu Lys Gly Ala
      85      90

```